Patients with mucosa-associated lymphoid tissue (MALT) lymphoma of the ocular adnexae (MLOA) will be eligible for treatment with doxycycline (part A: clinico-pathological study); patients with other types of ocular lymphoma, inflammatory lesions or those ineligible/unwilling for treatment with doxycycline can participate in the only pathologic study (part B).
Patients with suspected lymphoma of the ocular adnexae will undergo a diagnostic biopsy in the usual way. If lymphoma is confirmed the patient will undergo a full staging evaluation and entry into either part A or B of the study will then be considered as follows: * clinico-pathological (part A) for patients with MALT lymphoma of the ocular adnexae (MLOA) and eligible for treatment with Doxycycline 100 mg twice daily for 3 weeks ; or * pathology only (part B) for patients with other types of ocular lymphoma, inflammatory lesions or those ineligible/unwilling for treatment with doxycycline.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
54
doxycycline 100 mg twice daily for 3 weeks
Hospital del Salvador
Providencia, Santiago, Chile
Ospedale San Raffaele, Department of Oncology
Milan, Milan, Italy
S. Matteo
Pavia, Italy
A.O. Bianchi-Melacrino-Morelli, Divisione di Ematologia
Reggio Calabria, Italy
response rates
Time frame: at 6 weeks, 12 weeks, 12 months and 24 months from start of doxycycline
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Hospital Ramon y Cajal
Madrid, Spain
IOSI
Bellinzona, Switzerland